OBJECTIVE: Dopamine function has been hypothesized to be involved in both producing schizophrenic symptoms and mediating cocaine's reinforcing properties. As a result, cocaine abuse in schizophrenic patients may be seen as a natural experiment that may alter the phenomenology and neurobiology of schizophrenia. This report concerns the clinical effects of cocaine abuse and cessation in schizophrenic patients at two times: when patients presented to the psychiatric emergency service and again after 4 weeks of hospitalization. METHOD: The subjects were 15 cocaine-abusing and 22 cocaine-abstaining schizophrenic patients. Diagnostic assessments were performed with the Structured Clinical Interview for DSM-III-R--Patient Version, which uses DSM-III-R criteria. All of the patients were assessed at both times with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, and the Scale for the Assessment of Negative Symptoms. RESULTS: Cocaine-abusing schizophrenic patients showed fewer negative signs and more anxiety/depression at the hospital-admission assessment than their nonabusing counterparts. At retest, no group differences were detected in patients' negative signs or mood symptoms. Severity of positive symptoms was equal at both testing sessions. CONCLUSIONS: The significant difference in negative signs and mood symptoms at admission assessment was attributed to the neurobiological impact of cocaine. The role of psychostimulants in schizophrenic patients is discussed.
OBJECTIVE:Dopamine function has been hypothesized to be involved in both producing schizophrenic symptoms and mediating cocaine's reinforcing properties. As a result, cocaine abuse in schizophrenicpatients may be seen as a natural experiment that may alter the phenomenology and neurobiology of schizophrenia. This report concerns the clinical effects of cocaine abuse and cessation in schizophrenicpatients at two times: when patients presented to the psychiatric emergency service and again after 4 weeks of hospitalization. METHOD: The subjects were 15 cocaine-abusing and 22 cocaine-abstaining schizophrenicpatients. Diagnostic assessments were performed with the Structured Clinical Interview for DSM-III-R--Patient Version, which uses DSM-III-R criteria. All of the patients were assessed at both times with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, and the Scale for the Assessment of Negative Symptoms. RESULTS:Cocaine-abusing schizophrenicpatients showed fewer negative signs and more anxiety/depression at the hospital-admission assessment than their nonabusing counterparts. At retest, no group differences were detected in patients' negative signs or mood symptoms. Severity of positive symptoms was equal at both testing sessions. CONCLUSIONS: The significant difference in negative signs and mood symptoms at admission assessment was attributed to the neurobiological impact of cocaine. The role of psychostimulants in schizophrenicpatients is discussed.
Authors: David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen Journal: CNS Drugs Date: 2008 Impact factor: 5.749
Authors: Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss Journal: J Psychiatr Pract Date: 2005-09 Impact factor: 1.325
Authors: Caitlin E Carey; Arpana Agrawal; Kathleen K Bucholz; Sarah M Hartz; Michael T Lynskey; Elliot C Nelson; Laura J Bierut; Ryan Bogdan Journal: Front Genet Date: 2016-08-15 Impact factor: 4.599